The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents

On March 11, 2020, the World Health Organization (WHO) officially declared the outbreak caused by the new coronavirus (SARS-CoV-2) a pandemic. The rapid spread of the disease surprised the scientific and medical community. Based on the latest reports, news, and scientific articles published, there is no doubt that the coronavirus has overloaded health systems globally. Practical actions against the recent emergence and rapid expansion of the SARS-CoV-2 require the development and use of tools for discovering new molecular anti-SARS-CoV-2 targets. Thus, this review presents bioinformatics and molecular modeling strategies that aim to assist in the discovery of potential anti-SARS-CoV-2 agents. Besides, we reviewed the relationship between SARS-CoV-2 and innate immunity, since understanding the structures involved in this infection can contribute to the development of new therapeutic targets. Bioinformatics is a technology that assists researchers in coping with diseases by investigating genetic sequencing and seeking structural models of potential molecular targets present in SARS-CoV2. The details provided in this review provide future points of consideration in the field of virology and medical sciences that will contribute to clarifying potential therapeutic targets for anti-SARS-CoV-2 and for understanding the molecular mechanisms responsible for the pathogenesis and virulence of SARS-CoV-2.

[1]  M. Metra,et al.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.

[2]  Linqi Zhang,et al.  Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor , 2020, bioRxiv.

[3]  Harjeet Singh,et al.  Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome , 2020 .

[4]  B. Berkhout,et al.  Human coronavirus NL63, a new respiratory virus , 2006, FEMS microbiology reviews.

[5]  V. Martella,et al.  Canine Coronavirus Highly Pathogenic for Dogs , 2006, Emerging infectious diseases.

[6]  K. Yelekçi,et al.  Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10 , 2019, Journal of biomolecular structure & dynamics.

[7]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[8]  L. Larosa,et al.  Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab , 2020, Infection.

[9]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[10]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[11]  Bin Peng,et al.  In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus , 2020, Journal of Integrative Medicine.

[12]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[13]  C. Buonavoglia,et al.  Canine Coronavirus: Not Only an Enteric Pathogen , 2011, Veterinary Clinics of North America: Small Animal Practice.

[14]  B. Robson,et al.  Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus , 2020, Computers in Biology and Medicine.

[15]  Thomas Henry,et al.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions , 2020, Autoimmunity Reviews.

[16]  Federico M Giorgi,et al.  Genomic variance of the 2019‐nCoV coronavirus , 2020, Journal of medical virology.

[17]  Christine A. Biron,et al.  Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente , 2006, Science.

[18]  P. Schellen,et al.  Acquisition of Macrophage Tropism during the Pathogenesis of Feline Infectious Peritonitis Is Determined by Mutations in the Feline Coronavirus Spike Protein , 2005, Journal of Virology.

[19]  G. Rohrmann,et al.  Analysis of the genome sequence of an alpaca coronavirus , 2007, Virology.

[20]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[21]  P. Bhargava,et al.  Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 , 2020, International Journal of Infectious Diseases.

[22]  Jiasen Liu,et al.  Molecular characterization of HLJ-073, a recombinant canine coronavirus strain from China with an ORF3abc deletion , 2019, Archives of Virology.

[23]  Isaac I. Bogoch,et al.  Coast-to-coast spread of SARS-CoV-2 in the United States revealed by genomic epidemiology , 2020, medRxiv.

[24]  H. Saibil,et al.  Macromolecular structure determination by cryo-electron microscopy. , 2000, Acta crystallographica. Section D, Biological crystallography.

[25]  Jeremy C. Smith,et al.  Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface , 2020 .

[26]  M. Baker.  Making membrane proteins for structures: a trillion tiny tweaks , 2010, Nature Methods.

[27]  Syed Faraz Ahmed,et al.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, Viruses.

[28]  R. Groot,et al.  Natural History of a Recurrent Feline Coronavirus Infection and the Role of Cellular Immunity in Survival and Disease , 2005 .

[29]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[30]  G. Sen,et al.  Viruses and interferons. , 2001, Annual review of microbiology.

[31]  K. Tennekoon,et al.  Virtual Screening of Inhibitors Against Spike Glycoprotein of 2019 Novel Corona Virus: A Drug Repurposing Approach , 2020 .

[32]  P. Lemey,et al.  Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event , 2005, Journal of Virology.

[33]  Barry Robson,et al.  Suggestions for a Web based universal exchange and inference language for medicine , 2013, Comput. Biol. Medicine.

[34]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[35]  Jared Radbel,et al.  Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome , 2020, Chest.

[36]  M. U. Mirza,et al.  Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase , 2020, Journal of Pharmaceutical Analysis.

[37]  S. Richardson,et al.  Molecular Diagnosis of Severe Acute Respiratory , 2005 .

[38]  Joel B. Hagen,et al.  The origins of bioinformatics , 2000, Nature Reviews Genetics.

[39]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[40]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[41]  Shuyi Zhang,et al.  Novel SARS-like Betacoronaviruses in Bats, China, 2011 , 2013, Emerging infectious diseases.

[42]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[43]  Herman Tse,et al.  Interspecies transmission and emergence of novel viruses: lessons from bats and birds , 2013, Trends in Microbiology.

[44]  M. Marinaro,et al.  Prolonged depletion of circulating CD4+ T lymphocytes and acute monocytosis after pantropic canine coronavirus infection in dogs , 2010, Virus Research.

[45]  Le Zhang,et al.  Progress in molecular docking , 2019, Quantitative Biology.

[46]  S. Richardson,et al.  Molecular Diagnosis of Severe Acute Respiratory Syndrome , 2005, The Journal of Molecular Diagnostics.

[47]  D. Raoult,et al.  Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis , 2020, Travel Medicine and Infectious Disease.

[48]  Ralph Baric,et al.  SARS coronavirus and innate immunity , 2007, Virus Research.

[49]  Michael G. Katze,et al.  Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.

[50]  Wei Chen,et al.  Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.

[51]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[52]  M. Salmon,et al.  Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. , 2002, Blood.

[53]  Kunqian Yu,et al.  Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients , 2020, Acta Pharmacologica Sinica.

[54]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[55]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[56]  L. Papazian,et al.  Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome , 2020, Annals of Intensive Care.

[57]  Ogun Adebali,et al.  Phylogenetic analysis of SARS-CoV-2 genomes in Turkey , 2020, bioRxiv.

[58]  D. Raoult,et al.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.

[59]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[60]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[61]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[62]  M. Cascella,et al.  Features, Evaluation and Treatment Coronavirus (COVID-19) , 2020 .

[63]  Nizam Uddin,et al.  A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 , 2020, Journal of biomolecular structure & dynamics.

[64]  S. Weaver,et al.  Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin , 2020, bioRxiv.

[65]  M. Cotelli,et al.  Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome , 2020, Annals of the Rheumatic Diseases.

[66]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[67]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[68]  S. Weiss,et al.  Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus , 2005, Microbiology and Molecular Biology Reviews.

[69]  Wei Cui,et al.  Expression of Lymphocytes and Lymphocyte Subsets in Patients with Severe Acute Respiratory Syndrome , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[71]  A. Lorusso,et al.  Experimental infection of dogs with a novel strain of canine coronavirus causing systemic disease and lymphopenia , 2007, Veterinary Microbiology.

[72]  M. L. Serrano,et al.  Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis , 2020, EXCLI journal.

[73]  D. Hamer,et al.  Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge , 2020, International Journal of Infectious Diseases.

[74]  A. Sali,et al.  Structural genomics: beyond the Human Genome Project , 1999, Nature Genetics.

[75]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[76]  M. Everts,et al.  Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. , 2017, Annual review of pharmacology and toxicology.

[77]  M. Gismondo,et al.  Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status , 2020, Pharmacological Research.

[78]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[79]  T. Kanellos,et al.  Immunity after natural exposure to enteric canine coronavirus does not provide complete protection against infection with the new pantropic CB/05 strain , 2009, Vaccine.

[80]  G. Gao,et al.  Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.

[81]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[82]  Cédric Notredame,et al.  Multiple sequence alignment modeling: methods and applications , 2016, Briefings Bioinform..

[83]  S. Bose,et al.  Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV , 2020, Journal of medical virology.

[84]  A. Shanker,et al.  Whole-genome sequence analysis and homology modelling of the main protease and non-structural protein 3 of SARS-CoV-2 reveal an aza-peptide and a lead inhibitor with possible antiviral properties , 2020, New Journal of Chemistry.

[85]  Lunquan Sun,et al.  Current and future developments in the treatment of virus-induced hypercytokinemia , 2017, Future medicinal chemistry.

[86]  Mubarak A. Alamri,et al.  Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.

[87]  Kamel A. Abd-Elsalam,et al.  Bioinformatic tools and guideline for PCR primer design , 2003 .

[88]  Anoop Misra,et al.  Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[89]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[90]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  G. Whittaker,et al.  Genotypic Characterization of Canine Coronaviruses Associated with Fatal Canine Neonatal Enteritis in the United States , 2014, Journal of Clinical Microbiology.

[92]  Vijay S. Pande,et al.  SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery , 2013, PloS one.

[93]  Trupti Joshi,et al.  Quantitative assessment of relationship between sequence similarity and function similarity , 2007, BMC Genomics.

[94]  Xingyi Ge,et al.  The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future , 2020, Microbes and Infection.

[95]  James O Lloyd-Smith,et al.  Dynamically Modeling SARS and Other Newly Emerging Respiratory Illnesses: Past, Present, and Future , 2005, Epidemiology.

[96]  Hiroaki Kitano,et al.  COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms , 2020, Scientific Data.

[97]  P. Schellen,et al.  Gain, Preservation, and Loss of a Group 1a Coronavirus Accessory Glycoprotein , 2008, Journal of Virology.

[98]  Ning Wang,et al.  Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China , 2018, Virologica Sinica.

[99]  M. L. Serrano,et al.  Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target , 2020, EXCLI journal.

[100]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[101]  Colin Renfrew,et al.  Phylogenetic network analysis of SARS-CoV-2 genomes , 2020, Proceedings of the National Academy of Sciences.

[102]  M. Dubinsky,et al.  Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab , 2020, Journal of pediatric gastroenterology and nutrition.

[103]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[104]  Jian Ye,et al.  Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction , 2012, BMC Bioinformatics.

[105]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Laurence Miguet,et al.  Comparison of a homology model and the crystallographic structure of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a structure-based identification of inhibitors , 2006, J. Comput. Aided Mol. Des..

[107]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[108]  S. Baldovino,et al.  Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. , 2020 .

[109]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[110]  A. Scala,et al.  Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study , 2020, Marine drugs.

[111]  G. Dangas,et al.  Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.

[112]  C. Garlanda,et al.  Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.

[113]  P. Woo,et al.  Molecular diversity of coronaviruses in bats , 2006, Virology.

[114]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[115]  B. Foley,et al.  Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2 , 2020, Journal of medical virology.

[116]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[117]  G. Gao,et al.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.

[118]  Hongzhu Cui,et al.  Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins , 2020, Viruses.

[119]  Lisa E. Gralinski,et al.  Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.

[120]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[121]  A. Godzik,et al.  Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, bioRxiv.

[122]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[123]  P. Woo,et al.  Identification of a Novel Coronavirus in Bats , 2005, Journal of Virology.

[124]  Barry Robson,et al.  Drug discovery using very large numbers of patents. General strategy with extensive use of match and edit operations , 2011, J. Comput. Aided Mol. Des..

[125]  Jim Huggett,et al.  qPCR primer design revisited , 2017, Biomolecular detection and quantification.

[126]  Jianguo Tan,et al.  The impact of the COVID-19 epidemic on the utilization of emergency dental services , 2020, Journal of Dental Sciences.

[127]  Xingguang Li,et al.  Phylogenetic and phylodynamic analyses of SARS-CoV-2 , 2020, Virus Research.

[128]  J. Schwartz,et al.  Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. , 2011, ACS medicinal chemistry letters.

[129]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[130]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[131]  Jacques Fantini,et al.  Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[132]  L. Ferreira,et al.  Biotechnology applied to the development of vaccines , 2013 .

[133]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[134]  D. Raoult,et al.  Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France , 2020, Travel Medicine and Infectious Disease.

[135]  A. Manenti,et al.  Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2 , 2020, Medical Hypotheses.

[136]  M. Baba,et al.  The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[137]  R. Agha,et al.  World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) , 2020, International Journal of Surgery.

[138]  W. Savino.  The Thymus Is a Common Target Organ in Infectious Diseases , 2006, PLoS pathogens.

[139]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[140]  SARS Coronavirus Redux , 2020, Trends in Immunology.

[141]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[142]  G. Evans,et al.  The design of macromolecular crystallography diffraction experiments , 2011, Acta crystallographica. Section D, Biological crystallography.

[143]  H. McClure,et al.  Decreased CCR5 expression on CD4+ T cells of SIV-infected sooty mangabeys. , 2003, AIDS research and human retroviruses.

[144]  Zihe Rao,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, medRxiv.

[145]  A. Zangrillo,et al.  Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study , 2020, Annals of the Rheumatic Diseases.

[146]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[147]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[148]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[149]  G. Costantino,et al.  Use of anakinra in severe COVID-19: A case report , 2020, International Journal of Infectious Diseases.

[150]  John D Lambris,et al.  Clinical promise of next-generation complement therapeutics , 2019, Nature Reviews Drug Discovery.

[151]  Jie Li,et al.  Review of Drug Repositioning Approaches and Resources , 2018, International journal of biological sciences.

[152]  M. Netea,et al.  Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis , 2020, Cell Host & Microbe.

[153]  R. D. de Groot,et al.  Natural History of a Recurrent Feline Coronavirus Infection and the Role of Cellular Immunity in Survival and Disease , 2005, Journal of Virology.

[154]  S. Hashemian,et al.  Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial , 2020, International Immunopharmacology.

[155]  Li-Yeh Chuang,et al.  Specific primer design for the polymerase chain reaction , 2013, Biotechnology Letters.

[156]  M. Kiso,et al.  The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner , 2020, Viruses.

[157]  G. Whittaker,et al.  A Tale of Two Viruses: The Distinct Spike Glycoproteins of Feline Coronaviruses , 2020, Viruses.

[158]  Muhammed Tilahun Muhammed,et al.  Homology modeling in drug discovery: Overview, current applications, and future perspectives , 2018, Chemical biology & drug design.

[159]  P. Cecchini,et al.  COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients , 2020, Journal of medical virology.

[160]  A. Elfiky,et al.  Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 , 2020, Life Sciences.

[161]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[162]  Qibo Zhang,et al.  MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile , 2018, Cytokine.

[163]  G. Pelletier,et al.  A bioinformatics workflow for the evaluation of RT-qPCR primer specificity: Application for the assessment of gene expression data reliability in toxicological studies. , 2020, Regulatory toxicology and pharmacology : RTP.

[164]  Barry Robson,et al.  Data mining and clinical data repositories: Insights from a 667, 000 patient data set , 2006, Comput. Biol. Medicine.

[165]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[166]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[167]  David Spiro,et al.  Bovine-Like Coronaviruses Isolated from Four Species of Captive Wild Ruminants Are Homologous to Bovine Coronaviruses, Based on Complete Genomic Sequences , 2006, Journal of Virology.

[168]  Ning Wang,et al.  Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus , 2017, PLoS pathogens.

[169]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[170]  S. Perlman,et al.  Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.

[171]  P. Marchetti,et al.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.

[172]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[173]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[174]  C. Buonavoglia,et al.  An update on canine coronaviruses: Viral evolution and pathobiology , 2008, Veterinary Microbiology.

[175]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[176]  The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report , 2020, Nephron.

[177]  Ziding Zhang,et al.  Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins , 2020, bioRxiv.

[178]  Wael M. Elshemey,et al.  Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐hepatitis C virus drugs against human corona viruses , 2017, Journal of medical virology.

[179]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.